The origins of
@NervgenP
described as "a story of tragedy, a hope and a dream, and one for which the end is yet to be written" says
@NervGenP
founder in new book by
@jancavelle
Our lead drug candidate, NVG-291, is a first-in-class therapeutic that has the potential to enable repair of the nervous system. It’s currently being evaluated in a Phase 1b/2a clinical trial for individuals with spinal cord injury. View our full video to learn more:
NVG-291-R, developed by
@NervgenP
is focus of new animal stroke study, conducted by
@uofcincy
and
@cwru
which showed improved memory, motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset.
#ScienceTwitter
Advances in modern medicine allow for things once never thought possible, like the repair of nervous system damage. Watch the full video to learn more about the potential of NVG-291.
#biotech
#neuroscience
#innovation
NervGen Pharma Corp. is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of NVG-291 in individuals with spinal cord injury at the Shirley Ryan
@AbilityLab
in Chicago. Some of the eligibility requirements for this trial include:
▶ Age 18-75
▶
We believe our lead drug candidate, NVG-291, has the potential to promote groundbreaking nervous system repair and functional recovery in
#spinalcordinjuries
, and possibly in other neurological diseases like
#Stroke
#Alzheimers
or
#MS
.
Watch the full video:
"...for everything from sun tanning and swimming to beach volleyball and sandcastle building. But for all the activities and fun beaches offer, they often lack one very important thing: accessibility." Read more in this week's blog post!
#accessibility
NervGen Pharma Corp. announces we've made the 2024 TSX
#Venture50
list! The ranking by TSX Venture 50 recognizes the top 50 fastest growing companies on
#TSXV
in the past year.
@NervgenP
's President & CEO, Mike Kelly, talks about the significance of this recognition and the
NervGen announced plans for developing a new drug candidate, NVG-300, adding diversity to its pipeline incl. new potential indications: ischemic stroke, ALS.
Learn more about a new molecule that was discovered at NervGen:
#announcement
#stroke
#ALS
#SCI
NervGen recognizes March as Multiple Sclerosis Awareness month. Thank you to
@MSNewsToday
for reporting on our NVG-291 in healthy volunteers.
#MultipleSclerosis
@NervgenP
is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of NVG-291 in individuals with spinal cord injury at
@AbilityLab
in Chicago. Some of the eligibility requirements for this trial include:
▶ Age 18-75
▶ Cervical SCI resulting from acute
In 2009, Dr. Jerry Silver began focusing on creating treatments that enhance the repair of the nervous system by preventing signals that inhibit the repair process. In 2015, NVG-291 was identified. Watch the full video:
#spinalcordinjury
#meded
#DYK
Each year in the US approx. 18,000 spinal cord injuries are diagnosed.
NervGen’s lead drug candidate, NVG-291, is currently in
#clinicaltrials
in our lead indication,
#SCI
.
Q3 2023 financial results and key updates from
@NervgenP
:
🌟 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞: Phase 1a/2b trial of NVG-291 is in full swing.
🚀 𝐅𝐃𝐀 𝐑𝐞𝐜𝐨𝐠𝐧𝐢𝐭𝐢𝐨𝐧: NVG-291 has been granted Fast Track designation by the U.S. FDA for spinal cord injury.
🔍
NervGen Pharma Receives FDA Authorization To Expand Enrollment Of Males And Premenopausal Females In Phase 1 Clinical Trial Of NervGen’s NVG-291! Read full press release at link below.
“NervGen made considerable progress in the quarter to advance our landmark Phase 1a/2b clinical study of NVG-291 for individuals with spinal cord injury,” said Mike Kelly,
@NervgenP
's President & CEO.
↠
#spinalcord
@AbilityLab
“NVG-291’s ability to remyelinate and enhance plasticity is a one-two knockout punch for repairing a faulty central nervous system,” says Paul Brennan, CEO of
@NervgenP
, a biotech company.
@NervgenP
Reports 2023 Year-End Financial Results and Operational Updates:
• Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024
• CA$23 million bought deal financing completed in March 2024 provides expected cash runway
Our CONNECT SCI Study examines an investigational treatment, NVG-291, that has the potential to enable the nervous system to repair itself.
Learn more about eligibility requirements and enrollment:
#spinalcordinjury
Dr. Jerry Silver's research focuses on the glial scar which forms at sites of a physical injury such as spinal cord injury, as well as sites of damage from diseases such as Alzheimer’s and multiple sclerosis.
@cwru
@Wingsforlife
@abilitylab
#clinicaltrials
NervGen Pharma's (TSX-V: NGEN, OTCQX: NGENF) President & CEO, Paul Brennan, on repairing the nervous system in interview with Torrey Hills Capital.
NervGen’s drug, NVG-291, is moving rapidly towards Phase 1b/2 clinical trials for AD, SCI and MS.
.
@KarenJagoda
interviewed NervGen’s President & CEO, Mike Kelly, on the
#EmpoweredPatient
podcast about NervGen’s clinical program, and NVG-300, the new drug candidate announced earlier this week.
Listen here:
NervGen today announced that it will be presenting two posters at the upcoming
@ASIA_spine
Annual Scientific Meeting, being held May 20-23, 2024.
Read the full release here:
#NEWS
: NBC Chicago featured our CONNECT SCI Study, , with
@abilitylab
, highlighting the importance of clinical research to find a potential new approach in
#spinalcordinjury
treatment.
View NBC Chicago's segment:
NervGen receives approval to proceed to the final dose cohort in Phase 1 clinical trial of NVG-291 and reports Q1 2022 results. Read full press release at link below -
Read this Q&A with NervGen’s President & CEO, Mike Kelly, and
@Rob_TMM
of the
@medicine_maker
to learn about NervGen’s lead drug, NVG-291, and the ongoing clinical trial for spinal cord injury.
Read the full article:
#SCI
#SpinalCordInjury
A spinal cord injury occurs whenever there is damage to any part of the spinal cord. It can cause changes in feeling, movement, strength, and body functions below the site of injury.
Learn more about our CONNECT SCI Study:
#clinicaltrials
NervGen President & CEO, Mike Kelly, will be presenting a corporate update at the
@SciSymposium
on June 27, 2024, at 2 p.m. PDT during the Clinical Spinal Cord Injury Session.
Advanced registration is required. Learn more:
#SpinalCordInjury
NervGen’s President & CEO, Mike Kelly, spoke with
@chrisleidli
on the Rx for Biotech podcast about NervGen’s lead drug candidate, NVG-291, the company’s recent financial and operational milestones, and NervGen’s goals for the next few years.
NervGen Pharma Awarded Up To $1.5 Million US Department Of Defense Funding To Evaluate NervGen’s NVG-291-R For Peripheral Nerve Injury - click link to read full press release!
“
@nervgenp
developed a unique trial design to evaluate NVG-291’s ability to restore function in humans with SCI," says Mike Kelly, CEO. Read more in press release:
#Spinalcordinjury
#clinicaltrial
The CONNECT SCI Study website, , for our Phase 1b/2a clinical trial in
#spinalcordinjury
is now live.
The study involves NVG-291, an investigational treatment, that has the potential to enable the nervous system to repair itself.
#clinicaltrials
NervGen Pharma receives approval from safety review committee to proceed to second cohort in multiple ascending dose portion of Phase 1 clinical trial of NVG-291! Read full press release at link below.
#clinicaltrials
#drugdevelopment
#biotech
#research
Read about our plans to expand our pipeline of new molecules addressing high unmet need neurologic indications while remaining focused on our lead candidate, NVG-291, adding diversity to our pipeline and strategic partnering opportunities in
@BioWorld
.
NBC Chicago featured our CONNECT SCI Study, , with
@abilitylab
, highlighting the importance of clinical research to find a potential new approach in
#SpinalCordInjury
treatment.
View NBC Chicago's segment
NervGen announces the appointment of Neil Klompas, experienced life sciences executive and board member, to the company’s Board of Directors.
Read the full release here:
The CONNECT SCI Study for our Phase 1b/2a clinical trial in
#SpinalCordInjury
is enrolling subjects. The study involves NVG-291, an investigational treatment that has the potential to enable the nervous system to repair itself.
#SCI
#ClinicalTrials
“I’m a big believer in open-source information as much as possible,” says Nana Collett, VP, program management at
@NervgenP
. “I understand companies need proprietary information, but I’m a bit radical this way. I believe that as an ecosystem, we’re going to get stronger if we can
NervGen participated in
@SCISymposium
and our President & CEO, Mike Kelly, spoke with
@BrianOrelli
of
@BiotechTVHQ
about the progress of our lead drug candidate, NVG-291, currently being evaluated in a Phase 1b/2a clinical trial.
Paul Brennan, CEO,
@NervgenP
interviewed by
@KevinPriceLive
on the company's advances in spinal cord injury treatment. Listen to this nationally syndicated radio interview at link below:
NervGen today announced the results of its Annual General Meeting of Shareholders held on June 4, 2024. Also announced was the appointment of Glenn Ives as Chair of the Board and John Ruffolo as Chair of the Audit Committee.
Full release:
#announcement
𝐌𝐢𝐤𝐞 𝐊𝐞𝐥𝐥𝐲
@NervgenP
CEO who has “moved successfully through smaller biotech’s and commercial launches” on the importance of building and maintaining relationships with CDMO’s in
@OutsourcedPharm
.
#innovation
#biotech
NervGen will be presenting on August 13, 2024, 10 a.m. EDT at the Canaccord Genuity 44th Annual Growth Conference being held August 13-15, 2024, in Boston. The presentation will be webcast with a replay available following the event.
Full news release:
@NervgenP
(TSX-V: NGEN; OTCQX: NGENF), announced today that renowned neuroscientist, Dr. Jerry Silver, inventor of NervGen’s lead drug candidate, NVG-291, joined
@GuyKawasaki
on his acclaimed podcast, “Remarkable People.” The full news release is available at the link below:
NervGen Pharma Reports 2022 Year End Results And Provides Operational Update Including Plans To Initiate Phase 1b/2a Clinical Trial Of Proprietary NVG-291 in Q3 2023. Read full press release at link -
#drugdevelopment
#clinicaltrial
#spinalcordinjury
Paul Brennan, NervGen Pharma Corp ((TSX-V: NGEN, OTCQX: NGENF) President & CEO, on enabling the nervous system to repair itself in interview with Torrey Hills Capital.
NervGen is presenting on Sep. 10, at 9:30 a.m. EDT, at the H.C. Wainwright 26th Annual Global Investment Conference being held Sep. 9-11, 2024, in New York City, and will be available for 1-on-1 investor meetings at the conference.
Full news release:
Read the incredible story of Kathryn Simpson and how she learned to navigate new motherhood in the aftermath of a stroke.
#stroke
#inspiration
#motherhood
NervGen Pharma presenting at the upcoming 2022 American Academy of Neurology Annual Meeting, April 2-7. Read full press release at link below!
@AANMember
Learn more about
@NervgenP
spinal cord trial at
@AbilityLab
in FREE webinar this Friday at 12 noon ET.
Please click the link below to join the webinar on 1/14 at 12 noon ET:
NervGen Director of Research, Marc DePaul, is a keynote speaker at the 10th Annual Neuroscience Virtual Conference hosted by
@Labroots
on March 10, 2022. Check out the event at link below & register to attend!
#LRneuro
#neuroscience
#keynote
#biotech